Synapse - Tiffany Traina

Results (256)

Adjuvant (adj) bevacizumab (B) plus dose-dense (dd) doxorubicin/cyclophosphamide (AC) followed by nanoparticle albumin-bound paclitaxel (nab-p) in early stage breast cancer (BC) patients (pts): Cardiac safety

Meeting Abstract

Dickler, M. N.; Traina, T.; Panageas, K.; Steingart, R.; Dang, C.; Fornier, M.; Sugarman, S.; Norton, L.; Hudis, C.; Rugo, H.
Journal of Clinical Oncology (2007)

Fulltext@MSK | Save

Randomized phase II trial of three dosing schedules of nanoparticle albumin-bound paclitaxel with bevacizumab as first-line therapy for HER2-negative metastatic breast cancer: An initial interim safety report

Meeting Abstract

Conlin, A. K.; Seidman, A. D.; Moynahan, M. E.; Traina, T.; Mace, J. R.; Meiri, E.; Bach, A.; Edwards, C.; Hudis, C. A.
Journal of Clinical Oncology (2007)

Fulltext@MSK | Save

Cardiac safety of adjuvant bevacizumab plus dose-dense doxorubicin/cyclophosphamide followed by nanoparticle albumin-bound paclitaxel in patients with early stage breast cancer

Meeting Abstract

Mcarthur, H. L.; Rugo, H.; Paulson, M.; Rourke, M.; Traina, T.; Panageas, K.; Steingart, R.; Dang, C.; Fornier, M.; Park, J.; more...
Breast Cancer Research and Treatment (2007)

Fulltext@MSK | Save

Bevacizumab for advanced breast cancer

Journal Article

Traina, T. A.; Rugo, H. S.; Dickler, M.
Hematology/Oncology Clinics of North America (2007)

Fulltext@MSK | Save

In vivo activity of a novel regimen of capecitabine (C) in a breast cancer xenograft model

Meeting Abstract

Traina, T. A.; Theodoulou, M.; Higgins, B.; Kolinsky, K.; Packman, K.; Dugan, U.; Hudis, C. A.; Norton, L.
Breast Cancer Research and Treatment (2006)

Fulltext@MSK | Save

Optimizing chemotherapy administration: A phase I study of biweekly capecitabine dose and schedule based on Norton-Simon mathematical modeling

Meeting Abstract

Traina, T. A.; Theodoulou, M.; Dugan, U.; Feigin, K.; Panageas, K.; Hodgman, E.; Norton, L.; Hudis, C. A.
Breast Cancer Research and Treatment (2006)

Fulltext@MSK | Save

Letrozole (L) with bevacizumab (B) is feasible in patients (pts) with hormone receptor-positive metastatic breast cancer (MBC)

Meeting Abstract

Traina, T. A.; Rugo, H.; Caravelli, J.; Yeh, B.; Panageas, K.; Bruckner, J.; Norton, L.; Park, J.; Hudis, C.; Dickler, M.
Journal of Clinical Oncology (2006)

Fulltext@MSK | Save

Change in circulating endothelial cells (CEC) predicts progression free survival (PFS) in patients (pts) with hormone receptor positive metastatic breast cancer (MBC) receiving letrozole (L) and bevacizumab (B)